Stanford University
Showing 1-100 of 120 Results
-
Catherine Aftandilian
Clinical Associate Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsI conduct clinical research on the prevention, early diagnosis, and treatment of infectious complications in pediatric patients with leukemia.
-
Glaivy Batsuli, MD
Associate Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsHemophilia is a rare inherited X-linked bleeding disorder characterized by the deficiency of blood clotting proteins factor VIII or factor IX. These individuals are at risk for spontaneous bleeds and trauma or surgery-induced bleeding. There have been remarkable advancements in the management of hemophilia to prevent these bleeding episodes and improve quality of life. However, the presence of neutralizing antibodies, called inhibitors, still dictates access to novel therapies such as factor replacement for bleed management and now FDA-approved gene therapies. The Batsuli Lab is focused on elucidating mechanisms of the immune response to blood coagulation proteins in bleeding disorders in order to develop strategies and therapeutics for inhibitor prevention and tolerance induction.
Dr. Batsuli's clinical research interests also include clinical trial participation for novel therapeutics & interventions in bleeding disorders such as hemophilia and von Willebrand disease in addition to coagulation issues & outcomes in ultra-rare bleeding disorders and sickle cell disease. -
Xi Ying Amanda Chen
Postdoctoral Scholar, Stem Cell Transplantation
BioDr. Chen completed a Bachelor of Science (Honours) at the University of Sydney (NSW, Australia), with majors in Molecular Biology and Immunobiology. She graduated with the University Medal for her Honours research project where she investigated the novel role of DNA damage repair machinery on telomerase recruitment to telomeres. She then undertook her graduate studies at the Peter MacCallum Cancer Centre (The University of Melbourne, VIC, Australia) in the Beavis laboratory, where she developed a CRISPR knock-in strategy to engineer armored CAR T cells to express therapeutic payloads in a tumor-restricted manner. She joined the Porteus laboratory in the Department of Pediatrics at Stanford University in March 2025, where she is developing strategies to enhance gene-edited hematopoietic stem cell transplantation.
-
Harvey Cohen
Deborah E. Addicott - John A. Kriewall and Elizabeth A. Haehl Family Professor of Pediatrics, Emeritus
Current Research and Scholarly InterestsMy research interests extend from hypothesis-driven studies in biochemistry and cell biology to discovery-driven interests in proteomics and systems biology to clinical treatment of acute lymphoblastic leukemia of children, and pediatric palliative care.
-
Gary Dahl
Professor of Pediatrics (Hematology/Oncology), Emeritus
Current Research and Scholarly InterestsHematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.
-
Heike Daldrup-Link
Professor of Radiology (General Radiology) and, by courtesy, of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsAs a physician-scientist involved in the care of pediatric patients and developing novel pediatric molecular imaging technologies, my goal is to link the fields of nanotechnology and medical imaging towards more efficient diagnoses and image-guided therapies. Our research team develops novel imaging techniques for improved cancer diagnosis, for image-guided-drug delivery and for in vivo monitoring of cell therapies in children and young adults.
-
Kara Davis
Associate Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsChildhood cancers can be considered aberrations of normal tissue development. We are interested in understanding childhood cancers through the lens of normal development. Further, individual tumors are composed of heterogeneous cell populations, not all cells being equal in their ability to respond to treatment or to repopulate a tumor. Thus, we take single cell approach to determine populations of clinical relevance.
-
Pablo Domizi, Ph.D.
Senior Research Scientist-Basic Life, Pediatrics - Hematology/Oncology
BioI am passionate about translational research and how single cell technologies could open up new avenues for better and more accurate predictive models. Currently, I am focus on integrating single cell RNA and protein expression data to develop models to predict patient at risk for Antigen Loss relapse after CAR T cells immunotherapy.
-
Charles Gawad
Associate Professor of Pediatrics (Hematology/Oncology)
On Partial Leave from 02/01/2025 To 03/29/2026BioOur lab works at the interface of biotechnology, computational biology, cellular biology, and clinical medicine to develop and apply new tools for characterizing genetic variation across single cells within a tissue with unparalleled sensitivity and accuracy. We are focused on applying these technologies to study cancer clonal evolution while patients are undergoing treatment with the aim of identifying cancer clonotypes that are associated with resistance to specific drugs so as to better understand and predict treatment response. We are also applying these methods to understand how more virulent pathogens emerge from a population of bacteria or viruses with an emphasis on developing a deeper understanding of how antibiotic resistance develops.
-
Bertil Glader
Stanford Medicine Professor of Pediatric Hematology/Oncology, Emeritus
Current Research and Scholarly InterestsHematology/Oncology, biology, and treatment of bone marrow failure disorders, hereditary coagulation disorders-clinical trials.
-
Michael Jeng
Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsResearch interests focus on: 1) histiocytic disorders, such as Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH), and 2) vascular anomalies and malformations.
-
Claire Johns
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioFellowship: Pediatric Hematology Oncology Fellowship, Stanford Lucile Packard Children's Hospital 2022-2025
Residency: Pediatrics, University of California San Francisco 2019-2022
Medical School: University of California San Francisco, Class of 2019 -
Aanchal Preet Kaur
Postdoctoral Scholar, Hematology-Oncology
BioDr. Aanchal Preet Kaur is a post-doctoral fellow in the Ramakrishna lab interested in understanding the role of myeloid cells in driving immunosuppression and resistance to CAR T cell therapies in pediatric patients with diffuse midline glioma. Her work involves developing organoid models to study the interaction of myeloid cells and CAR T cells and further employ these models to validate targets identified in patient single cell sequencing data using CRISPR technology.
Dr. Aanchal Preet Kaur received her PhD in Oncology at the University of Nottingham, United Kingdom where she focused on developing dendritic cell vaccines for melanoma. In her earlier post-doctoral work at Providence Cancer Institute with Dr. Michael Gough, she developed spheroid models to study the impact of radiation therapy on immune cell-cancer cell interactions. -
Yong Yean Kim
Assistant Professor of Pediatrics ( Hematology & Oncology)
BioOur lab is interested in translational science to bring new therapies to clinical trials. In particular, we are interested in pediatric sarcomas which have not had advancement in clinical treatment for decades. Current projects in the lab focus on understanding of the biology of fusion transcription factor PAX3::FOXO1 which is the driver mutation in fusion positive rhabdomyosarcoma. PAX3::FOXO1 is a powerful oncogenic transcription factor which rewires the transcriptional organization to lock the cancer cell in the proliferative state. Since transcription factors including PAX3::FOXO1 are difficult to target using small molecules, we aim to understand how PAX3::FOXO1 is regulated and targeting the regulators of PAX3::FOXO1. By understanding and targeting the regulation of PAX3::FOXO1, we hope to bring new therapies for fusion positive rhabdomyosarcoma. Additionally, these regulatory mechanisms may also be active in other transcription driven cancers such as the EWSR1::FLI1 driven Ewings Sarcoma.
Our lab is also interested in exploring the epigenetic landscape of pediatric solid tumors and trying to understand how dysregulation in the epigenome drives oncogenesis. We utilize various CRISPR mediated genetic techniques to interrogate the regulators of epigenome focusing on the histone lysine demethylases (KDMs). KDMs are an understudied group of epigenetic regulators which can be targeted for therapeutic effect. We explore the role of KDMs in pediatric solid tumors and hope to identify potential targets for drug development. -
Norman J. Lacayo, MD
Associate Professor of Pediatrics (Hematology and Oncology)
Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.
-
Michael Link
Lydia J. Lee Professor of Pediatric Cancer
Current Research and Scholarly InterestsHematology/Oncology, treatment of sarcomas of bone and soft tissue, biology of acute lymphoblastic leukemias, treatment of non-Hodgkin's lymphoma and Hodgkin's disease.
-
Y. Lucy Liu, MD, PhD
Senior Research Scientist, Pediatrics - Hematology/Oncology
Current Role at StanfordSenior Research Scientist
-
Clara Lo
Clinical Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsResearch interests include:
Biomarkers and targeted therapy in pediatric immune thrombocytopenia
Transfusion-related iron overload
Hemophilia and other rare bleeding disorders
Thrombophilia -
Adrienne H. Long, MD, PhD
Instructor, Pediatrics - Hematology & Oncology
BioAdrienne H. Long, MD, PhD is an Instructor and Physician-Scientist in the Division of Pediatric Hematology and Oncology at the Lucile Packard Children's Hospital, Stanford. Clinically, she completed her MD at Northwestern University, her pediatrics residency at Boston Children’s Hospital, and her oncology fellowship training at Stanford University. Dr. Long sees patients with leukemias/lymphomas, and has a clinical interest in T cell malignancies.
Dr. Long received her PhD in Microbiology/Immunology through a National Institutes of Health (NIH) – Northwestern University partnership, where she worked with Dr. Crystall Mackall to advance CAR T cell therapies. Her influential thesis work was the first to identify T cell exhaustion as a critical factor limiting efficacy of CAR therapies (Long et al., Nature Medicine, 2015). She continued her research training with Dr. Nicholas Haining at the Dana Farber Cancer Institute during residency and is currently conducting her post-doctoral research with Dr. Mark Davis at Stanford.
Dr. Long’s research interests lie at the intersection of the immune system and cancer therapies. She is currently studying how thymic selection, designed to prevent auto-immunity, may also inhibit anti-tumor immunity in children. She is also interested in how immunotherapies that have revolutionized how we treat cancer can impact the developing pediatric immune system long term. -
Crystal Mackall
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.
-
Neyssa Marina
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emerita
Current Research and Scholarly InterestsGerm cell tumors and bone sarcomas.
-
Allison Pribnow
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsSolid Tumors, Bone Sarcomas, Global Oncology, Health Disparities
-
Sneha Ramakrishna
Assistant Professor of Pediatrics (Hematology/Oncology)
BioSneha Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In medical school, through the Howard Hughes Medical Research Scholar Award, she joined Dr. Crystal Mackall’s laboratory, where she designed and developed various GD2 CAR-Ts and tested them in preclinical models. During her residency training in Pediatrics at the Children’s Hospital of Philadelphia, she cared for some of the first patients treated with CD19 CAR T cells, learning the power of this therapy first-hand. During her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program, she worked with Dr. Terry Fry. She evaluated the mechanism of CD22 CAR T cell relapse in patients by developing an antigen escape model and establishing a deeper understanding of the effects of antigen density on CAR-T phenotype, expansion, and persistence (Fry…Ramakrishna…Mackall Nat Med, 2018; Ramakrishna, et al., Clinical Cancer Research, 2019). Since arriving at Stanford, Dr. Ramakrishna leads an interdisciplinary team that designs, develops, and successfully implements a robust correlative science platform for our novel CAR-T therapies. Analyzing patient samples from our first-in-human GD2 CAR-T trial (NCT04196413) treating a universally fatal cancer, diffuse midline glioma (DMG), we identified that intracerebroventricular CAR-T administration correlates with enhanced pro-inflammatory cytokines and reduced immunosuppressive cell populations in cerebrospinal fluid as compared to intravenous CAR-T administration (Majzner*, Ramakrishna*, et al., Nature 2022 *co-first authors). Her research program evaluates unique sets of patient samples using novel single-cell immune profiling to identify the drivers of CAR-T success or failure. Building on these findings, her team assesses approaches to enhance CAR-T efficacy and translate these findings to the clinic.
Clinically, Dr. Ramakrishna cares for children with solid tumors and treats hematologic, solid, and brain tumor pediatric patients with CAR T cell therapies in the Cancer Cellular Therapies program. -
Brian Richter
Adm Svcs Admstr 2, Pediatrics - Hematology/Oncology
Current Role at StanfordAssociate Director of Division Operations, Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation, & Regenerative Medicine
-
Katherine Jane Ryan
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
Clinical Assistant Professor (By courtesy), Adult NeurologyCurrent Research and Scholarly InterestsDr. Katherine “Katie” Ryan is a pediatric neuro-oncologist whose research focuses on developing and translating cellular immunotherapies for children with malignant brain tumors. She leads the first-in-human trial of GPC2-directed CAR T cells for CNS Embryonal Tumors. As a member of Stanford Children’s world-renowned pediatric brain tumor team, she diagnoses and treats children with CNS tumors while advancing innovative trial design, intracerebroventricular delivery, and correlative science.
-
Raya Saab
Lindhard Family Professor of Pediatric Cancer Biology
BioOur laboratory focuses on investigating molecular mechanisms of oncogene-induced tumorigenesis and tumor suppressor pathways, and oncogenic signaling in the pediatric solid tumor rhabdomyosarcoma. Our earlier work identified the tumor suppressors p53 and p18Ink4c as inhibitors of Cyclin D1-driven tumorigenesis in a pineoblastoma model, through senescence induction, and highlighted distinct roles for the the RB and p53 pathways in induction and maintenance of oncogene-induced senescence. We also identified CDK2 as a potential target for inducing senescence in premalignant lesions to inhibit tumor progression.
Our current focus is on studying oncogenic signaling and tumor suppression in the childhood tumor rhabdomyosarcoma, to identify key mediators of invasion and metastasis, which is the most common cause of treatment failure clinically. We use preclinical in vitro and in vivo models, including murine and human cell lines, and mouse models of disease.
We have recently uncovered a paracrine role for rhabdomyosarcoma-secreted exosomes in impacting biology of stromal cells. Rhabdomyosarcoma-derived exosomes carry specific miRNA cargo that imparts an invasive and migratory phenotype on normal recipient fibroblasts, and proteomic analysis revealed specific and unique pathways relevant to the two different molecular rhabdomyosarcoma subtypes that are driven by distinct oncogenic pathways. We identified that the driver oncogene in fusion-positive rhabdomyosarcoma, PAX3-FOXO1, modulates exosome cargo to promote invasion, migration, and angiogenic properties, and identified specific microRNA and protein cargo acting as effectors of PAX3-FOXO1 exosome-mediated signaling, including modulation of oxidative stress response and cell survival signaling.
Our ongoing work is focused on interrogating specific paracrine signaling pathways and molecular mechanisms of metastatic disease progression in rhabdomyosarcoma, for potential therapeutic targeting. -
Julien Sage
Elaine and John Chambers Professor of Pediatric Cancer and Professor of Genetics
Current Research and Scholarly InterestsWe investigate the mechanisms by which normal cells become tumor cells, and we combine genetics, genomics, and proteomics approaches to investigate the differences between the proliferative response in response to injury and the hyperproliferative phenotype of cancer cells and to identify novel therapeutic targets in cancer cells.
-
Kathleen M. Sakamoto
Shelagh Galligan Professor in the School of Medicine
Current Research and Scholarly InterestsMy research focuses on the molecular pathways that regulate normal and aberrant blood cell development, including acute leukemia and bone marrow failure syndromes. We are also studying novel drugs for treatment of cancer.
-
Mona D. Shah, MD, MBA
Adjunct Clinical Associate Professor, Pediatrics - Hematology & Oncology
BioDr. Mona Shah is a pediatric hematologist-oncologist, who earned her MD degree at the University of Maryland in 2001. She completed both her categorical pediatrics and global health residencies in 2004, followed by a pediatric hematology-oncology fellowship in 2007. She earned her MS in Clinical Investigation as part of the Clinical Scientist Training Program (CSTP) at Baylor College of Medicine in 2011, and more recently, completed an Executive MBA at Rice University Jones School of Business in 2018.
Dr. Shah was an Associate Professor at Baylor College of Medicine (2007 - 2020) in both Pediatrics and Medicine, local site PI on a number of pediatric hemostasis/thrombosis clinical trials, and spent 10 years as an Associate Medical Director of Clinical Operations, Quality, and Safety at Texas Children’s Hospital, Houston, TX.
Dr. Shah joined Genentech (a Member of the Roche Group)’s Rare Blood Disorders Franchise (Product Development - Oncology-Hematology) in February 2020, quickly advancing to Lead Medical Director, where she served as Medical Monitor for 2 Phase III Clinical Trials (crovalimab in atypical hemolytic uremic syndrome, aHUS). She was also engaged with the Renal Franchise (I2O) in developing crovalimab in Lupus Nephritis (Phase I & II Clinical Trials in development), and with Human Factors/Pediatric Formulations Working Group on autoinjector devices and oral formulations.
After completing a rotation in Early Development Safety (EDS), she was promoted to Senior Medical Safety Director in Late Stage Product Development, and was appointed Safety Strategy Lead for giredestrant in early and metastatic breast, ovarian, and endometrial cancer global clinical trials. She has experience in innovative study designs (adaptive/multi-drug), with FDA/EMA pediatric investigational plans, and health authority interactions. In June 2023, she was appointed Pediatric Safety Lead, in collaboration with the iPODD Team, supporting safety for pediatric indications and devices, and serves as the Co-Chair of the Pediatric Safety Expert Group.
Dr. Shah has kept and completed a bucket list since she was 7 years old (keeps growing): Running wild bouldering/rock climbing as a child in the Shenandoah/Blue Ridge Mountains, swimming with dolphins/piranhas in the Amazon, climbing inside a volcano caldera in Iceland, snorkeling the Great Barrier Reef ... have passport/will travel!
Since July 2022, she has joined Stanford University School of Medicine, as an Adjunct Clinical Associate Professor in the Department of Pediatrics, Division of Hematology-Oncology, where she enjoys teaching MSII students, and at the bedside in the Lucille Packard Bass Center Hematology Clinic. Dr. Shah enjoys free time in her new home base near San Francisco, where she hosts her visiting parents, friends, and extended family. -
Stephanie Melissa Smith
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsI am involved with clinical research related to cancer survivorship, with a particular focus on late effects of childhood cancer treatments and community partnerships to improve health equity for adolescent/young adult cancer survivors in under-resourced settings.
